Plans have been submitted to construct a large VIP lounge with a sea-facing balcony at a landmark entertainment venue. The Brighton Centre, located… ...

A 1-year-old boy was rushed to the hospital after falling from a balcony in Maspeth, Queens on Tuesday.

A Markland Hill man’s battle to build an extension – with a balcony – on the back of his house has failed due to privacy concerns.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying patients. Semaglutide, the first weekly GLP-1 RA for weight management ...

Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform.

Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers.

Two students had a narrow escape with the help of locals after a fire broke out at a girls' hostel in Greater Noida today. A video of the incident has gone viral.

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes drugs by 38% to $139B. REad more here.

Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial We think Novo’s stock looks slightly overvalued after this announcement.

Novo Nordisk's amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 weeks ...